- A federal advisory panel will review a proposal for the first in human test of CRISPR/cas9 gene-editing technology, according to the National Institutes of Health (NIH).
- Researchers at the University of Pennsylvania plan to edit two genes in T-cells using CRISPR in a study aimed at targeting myeloma, melanoma, and sarcoma tumor cells, reports MIT Technology Review.
- The study proposal will be reviewed by the Recombinant DNA Advisory committee (RAC) at its meeting to be held on June 21 and 22.
Read at BioPharma Dive
